| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA154623
Max Phase: Preclinical
Molecular Formula: C20H12F7NO4
Molecular Weight: 463.31
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C(O)C1=C(C(=O)Nc2c(F)c(F)c(-c3cccc(OC(F)(F)F)c3)c(F)c2F)CCC1
Standard InChI: InChI=1S/C20H12F7NO4/c21-13-12(8-3-1-4-9(7-8)32-20(25,26)27)14(22)16(24)17(15(13)23)28-18(29)10-5-2-6-11(10)19(30)31/h1,3-4,7H,2,5-6H2,(H,28,29)(H,30,31)
Standard InChI Key: HXVDQTDBVMYWOO-UHFFFAOYSA-N
Associated Targets(Human)
DHODH Tclin Dihydroorotate dehydrogenase (2737 Activities)
Associated Targets(non-human)
Dhodh Dihydroorotate dehydrogenase (165 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Dhodh Dihydroorotate dehydrogenase (104 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 463.31 | Molecular Weight (Monoisotopic): 463.0655 | AlogP: 5.31 | #Rotatable Bonds: 5 |
| Polar Surface Area: 75.63 | Molecular Species: ACID | HBA: 3 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 2.44 | CX Basic pKa: | CX LogP: 5.81 | CX LogD: 2.30 |
| Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.47 | Np Likeness Score: -0.59 |
References
| 1. Leban J, Saeb W, Garcia G, Baumgartner R, Kramer B.. (2004) Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement., 14 (1): [PMID:14684297] [10.1016/j.bmcl.2003.10.021] |
| 2. Leban J, Kralik M, Mies J, Gassen M, Tentschert K, Baumgartner R.. (2005) SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors., 15 (21): [PMID:16143532] [10.1016/j.bmcl.2005.07.053] |
| 3. Baumgartner R, Walloschek M, Kralik M, Gotschlich A, Tasler S, Mies J, Leban J.. (2006) Dual binding mode of a novel series of DHODH inhibitors., 49 (4): [PMID:16480261] [10.1021/jm0506975] |
| 4. Mancini RS, Barden CJ, Weaver DF, Reed MA.. (2021) Furazans in Medicinal Chemistry., 64 (4.0): [PMID:33569941] [10.1021/acs.jmedchem.0c01901] |
Source
Source(1):